Bone marrow microvascular density and angiogenic growth factors in multiple myeloma

被引:28
|
作者
Alexandrakis, MG
Passam, FJ
Ganotakis, E
Dafnis, E
Dambaki, C
Konsolas, J
Kyriakou, DS
Stathopoulos, E
机构
[1] Univ Hosp Heraklion, Dept Hematol, Iraklion, Crete, Greece
[2] Sotiria Hosp Med Sch Athens, Dept Internal Med 3, Hematol Unit, Athens, Greece
[3] Univ Hosp Heraklion, Dept Internal Med, Iraklion, Crete, Greece
[4] Univ Hosp Heraklion, Dept Nephrol, Iraklion, Crete, Greece
[5] Univ Hosp Heraklion, Dept Pathol, Iraklion, Crete, Greece
[6] Gen Hosp Rhodes, Blood Transfus Dept, Rhodes, Greece
[7] Univ Hosp Larisa, Dept Hematol, Larisa, Greece
关键词
hepatocyte growth factor; tumor necrosis; factor-alpha; angiogenesis; multiple myeloma;
D O I
10.1515/CCLM.2004.230
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
There is evidence that angiogenesis plays an important role in the progression of multiple myeloma (MM). Hepatocyte growth factor (HGF) and tumor necrosis factor-alpha (TNF-alpha) are cytokines that potently stimulate angiogenesis. We evaluated the microvascular density (MVD) of bone marrow biopsies (after immunostaining with antiCD34 antibodies) and serum levels of HGF and TNF-alpha in 43 patients with newly diagnosed MM. Twentyfour of these patients reached a plateau phase after treatment and were reevaluated for MVD, HGF and TNF-alpha. MVD values and serum levels of HGF and TNF-alpha were elevated in newly diagnosed MM patients in comparison with healthy controls. Pretreatment MVD, HGF and TNF-alpha increased with advancing stage of MM disease. In patients reaching the plateau phase, a significant reduction in MVD, HGF and TNF-alpha levels occurred. A positive correlation was noted between pretreatment MVD and serum levels of TNF-alpha and lactic dehydrogenase but not with HGF. However, HGF strongly correlated with beta(2)-microglobulin (beta(2)M), TNF-alpha and lactate dehydrogenase (LDH). We conclude that angiogenesis in MM, as expressed by the bone marrow MVD and the serum levels of angiogenic molecules such as HGF and TNF-alpha, increases with advancing clinical stage and decreases after effective chemotherapy.
引用
收藏
页码:1122 / 1126
页数:5
相关论文
共 50 条
  • [31] Bone marrow angiogenesis in multiple myeloma
    A Vacca
    D Ribatti
    [J]. Leukemia, 2006, 20 : 193 - 199
  • [32] Bone marrow transplantation and multiple myeloma
    Pacalo, CR
    [J]. LABORATORY MEDICINE, 2003, 34 (01) : 17 - 17
  • [33] Multiple Myeloma Bone Marrow Niche
    Basak, Grzegorz Wladyslaw
    Srivastava, Anand S.
    Malhotra, Rakesh
    Carrier, Ewa
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2009, 10 (03) : 335 - 346
  • [34] BONE MARROW EMBOLISM IN MULTIPLE MYELOMA
    KNOBLICH, R
    KREINER, E
    [J]. VIRCHOWS ARCHIV ABTEILUNG A PATHOLOGISCHE ANATOMIE, 1969, 347 (02): : 153 - &
  • [35] Bone marrow transplantation in multiple myeloma
    Schlossman, RL
    Anderson, KC
    [J]. CANCER INVESTIGATION, 1997, 15 (01) : 65 - 75
  • [36] Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma
    Sezer, O
    Niemöller, K
    Eucker, J
    Jakob, C
    Kaufmann, O
    Zavrski, I
    Dietel, M
    Possinger, K
    [J]. ANNALS OF HEMATOLOGY, 2000, 79 (10) : 574 - 577
  • [37] Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma
    O. Sezer
    K. Niemöller
    J. Eucker
    C. Jakob
    O. Kaufmann
    I. Zavrski
    M. Dietel
    K. Possinger
    [J]. Annals of Hematology, 2000, 79 : 574 - 577
  • [38] Bone marrow imaging of bone marrow transplanted multiple myeloma patients
    Agren, B
    Rudberg, U
    Mare, K
    Aspelin, P
    [J]. CLINICAL NUCLEAR MEDICINE, 1997, 22 (02) : 80 - 92
  • [39] Angiogenic factor levels in bone marrow and serum of multiple myeloma patients are not applicable to predict response to chemotherapy
    Vadasz, Gy.
    Radvanyi, G.
    Tarkanyi, I.
    Barath, S.
    Udvardy, M.
    [J]. BLOOD REVIEWS, 2007, 21 : S128 - S128
  • [40] PROGNOSTIC FACTORS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MULTIPLE-MYELOMA
    GAHRTON, G
    TURA, S
    LJUNGMAN, P
    BLADE, J
    BRANDT, L
    CAVO, M
    FACON, T
    GRATWOHL, A
    HAGENBEEK, A
    JACOBS, P
    DELAURENZI, A
    VANLINT, M
    MICHALLET, M
    NIKOSKELAINEN, J
    REIFFERS, J
    SAMSON, D
    VERDONCK, L
    DEWITTE, T
    VOLIN, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) : 1312 - 1322